scholarly journals Capitalizing on Fear and Failure: For-Profit Colleges Selling Themselves to the Poor

2020 ◽  
Author(s):  
Courtney Campbell ◽  
Regina Deil-Amen ◽  
Jessica Gjerde

Abstract This study explores the admissions encounter that prospective undergraduates experience at many for-profit colleges and universities (FPCUs). We consider how this encounter is shaped by intentional sales techniques and the implications of that approach for the college enrollment choices of low-SES and low-achieving students. Using the content of an admissions and recruitment staff training manual from a for-profit college with a publicly traded parent corporation and interviews from 47 students who went through the admissions and enrollment process at a for-profit college, we explore how recruiting practices are relevant to students’ college choice and to our rethinking of how college choice operates for students who are very similar to community college populations. Our data reveal for-profit admissions representatives, despite their good intentions, are incentivized to work as institutional agents in service of the institution’s profit motive at the expense of the student. FPCUs use admissions representatives to recruit prospective students by presenting the benefits of enrolling in a way that capitalizes on student anxieties, stress, and fear.

2018 ◽  
Vol 6 (7) ◽  
pp. 65
Author(s):  
P. Anbarasan

The study comprehensively analysis going green policy as a tangible approach to achieving sustainable development in any enterprise. Although business is conducted for profit motive sustaining the profit and enterprise competitive advantage is mainly related to an enterprise vision and values that incorporate in their management policies, hence the study analyzes the complex structure that related to sustainability and policy through causal loop diagram (CLD) of system dynamics and put forth capability advancement for sustainable development policy initiatives. Finally, the growth strategy and future scope of the study is discussed.


2011 ◽  
Vol 72 (6) ◽  
pp. 568-582 ◽  
Author(s):  
Jinnie Y. Davis ◽  
Mignon Adams ◽  
Larry Hardesty

For-profit schools constitute the fastest-growing sector of higher education institutions in the United States.1 Yet accompanying the phenomenal growth of these proprietary colleges and universities has been considerable controversy over the role that the profit motive should play in higher education.2 The literature of higher education contains increasingly more works about proprietary schools. The library literature, however, offers little in this arena. Through this article, the authors seek to introduce the library readership to U.S. for-profit colleges and universities. We summarize their history and their characteristics, and we explore reasons for their success and present areas in which these schools appear to excel. With regard to their library services and resources, we focus on issues of concern based specifically on our experience with academic libraries in proprietary schools operating in the state of Ohio. Finally, we suggest ways in which these for-profit institutions can address the challenges faced by their libraries.


2014 ◽  
Vol 116 (8) ◽  
pp. 1-34 ◽  
Author(s):  
Constance Iloh ◽  
William G. Tierney

Background/Context Scarce research has been conducted examining why students choose to attend higher priced for-profit institutions over community colleges. The authors suggest that increased national concern over proprietary higher education warrants an in-depth comparative case study of the choice factors utilized by for-profit and community college students. Research Question The research questions guiding this analysis are: (a) Why and how do students choose to attend for-profit colleges and community colleges? (b) What factors were important in their decision? (c) What implications do these results have for rational choice and college choice theory? Setting Data were collected at one community college and one for-profit college in California that had similar vocational programs. Subjects A total of 137 for-profit and community college students (75 for profit, 62 community college) enrolled in a vocational nursing or surgical technician associate's degree program agreed to participate. Research Design The authors examine student college choice factors through a case study. The findings were developed from interviews, surveys, and focus groups. Findings The authors found that for-profit and community college students held varying conceptions of costs and benefits as they pertained to college choice factors. Three particular dimensions were highlighted in student responses—short-term and long-term gains, risks, and uncertainty. Conclusions This study illuminates the nuanced factors and goals that informed student college choice decisions. Understanding these distinct college choice considerations could help researchers, practitioners, and institutional leaders develop measures for institutional effectiveness and student success.


2020 ◽  
pp. 147612702092125
Author(s):  
Dane P Blevins ◽  
Roberto Ragozzino ◽  
Rory Eckardt

Corporate governance has received substantial scholarly attention for decades, although the focus of this research has by and large been on publicly traded for-profit organizations. However, agency problems are increasingly recognized in nonprofits. As such, we examine the application of corporate governance logic in the context of nonprofits. Our study relies on nearly a decade of data spanning 6853 US-based charities and comprising nearly US$346 billion in total revenue. Our results show that common corporate governance practices—such as independent boards, chief executive officer oversight, and transparency—enhance the degree to which donor contributions are allocated toward a charity’s mission. Overall, we assess the broader applicability and benefits of corporate governance and build on literature highlighting links between for-profit and nonprofit organizations. In doing so, we demonstrate the usefulness of governance in this economically and socially consequential context.


2015 ◽  
pp. 8-10
Author(s):  
Andres Bernasconi

For-profit higher education is controversial. The legitimacy of the profit motive in education is called into question by those who believe that a trust-based relationship cannot be mediated by economic gain. Proponents of education as a legitimate business, for their part, argue that competition and market discipline are at once good for business and for quality education. They also maintain that in the absence of profit-seeking entrepreneurship we would not be seeing the enormous expansion of enrollments characteristic of higher education in the developing world. At any rate, if the nature of the institution is to be a choice for students, they need to be properly informed about whether the institution of their choice is for-profit.


1981 ◽  
Vol 12 (1) ◽  
pp. 15-18 ◽  
Author(s):  
Ralph E. Matkin ◽  
V. Robert May

The potential for conflicts of interest to arise in the private for-profit rehabilitation sector has been a major concern among professionals in the field for a number of years. Central to the issue have been factors such as the strong profit motive, the diversity of background and qualification levels among private practitioners, and the lack of regulations to govern the activities of the private rehabilitation sector. As the field of rehabilitation continues to strive toward attaining professional status, efforts by the private sector to reduce potential conflicts of interest are necessary. Development of enforceable ethical codes, enhanced professional authority, and the use of program evaluation are among the measures suggested to reduce potential conflicts of interest in the private sector.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 1-2
Author(s):  
Paul G. Richardson ◽  
Ajay Nooka ◽  
Hang Quach ◽  
Suzanne Trudel ◽  
David Routledge ◽  
...  

Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, induced deep and durable responses in patients with RRMM, with a manageable safety profile with 13 months of follow-up (DREAMM-2; NCT03525678; Lonial et al, ASCO 2020, Poster 436). A platform trial design allows efficient evaluation of belamaf in combination with other anti-myeloma agents, such as a humanized wild-type IgG1 anti-OX40 agonist, an IgG4-inducible T-cell co-stimulator (ICOS) agonist, a gamma-secretase inhibitor, and a humanized programmed cell death (PD)-1 antagonist. The unique, multimodal mechanisms of action (MoAs) of belamaf, in combination with MoAs of these agents, has the potential to achieve synergistic effects in RRMM to further enhance anti-myeloma activity without compromising safety. Methods: DREAMM-5 (NCT04126200) is a Phase I/II study that utilizes a master protocol with separate substudies comprised of sequential dose-exploration (DE) and cohort-expansion (CE) phases, to identify promising, effective belamaf combinations when compared with a shared single-agent belamaf control arm (CE phase only). The DE phase consists of multiple dosing cohorts with belamaf combinations in which patients are assigned to treatment slots by a predetermined algorithmic approach (N≤10 per cohort). A recommended Phase II dose (RP2D) for each combination treatment will be identified based on the safety and preliminary efficacy in the DE phase. At the end of the DE phase, an interim analysis of safety, pharmacokinetic, and efficacy data will also be performed for each substudy treatment combination to determine whether the combination should move forward at the RP2D to the CE phase. Patients in the CE phase (N≥35 per cohort) will be randomized to a substudy and within a substudy to either combination treatment or the belamaf monotherapy control arm; patients will also be stratified by number of prior therapies). Eligible patients will have RRMM and will have received ≥3 prior therapy lines, which includes a prior immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody; all patients will provide informed consent for participation. The primary objectives of the study are to identify the RP2D (DE phase) and the overall response rate (≥partial response, CE phase), along with safety and tolerability, for each combination treatment. Substudies 1 (combination with GSK3174998, OX40 agonist antibody), 2 (combination with GSK3359609, ICOS agonist antibody), and 3 (combination with nirogacestat [PF-03084014; SpringWorks Therapeutics], gamma-secretase inhibitor) are currently open to enrollment. Substudy 4 (combination with dostarlimab; PD-1 antagonist antibody) is under review. Additional substudies will be explored based on scientific rationale and/or preclinical combination study results. Funding: GSK (Study 208887); belamaf drug linker technology licensed from Seattle Genetics; belamaf monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa; nirogacestat gamma-secretase inhibitor produced by and used in collaboration with SpringWorks Therapeutics. Figure: DREAMM-5 study design Figure 1 Disclosures Richardson: Celgene/BMS, Oncopeptides, Takeda, Karyopharm: Research Funding. Nooka:GlaxoSmithKline: Consultancy, Honoraria, Other: Personal Fees: Travel/accomodations/expenses, Research Funding; Karyopharm Therapeutics, Adaptive technologies: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Spectrum Pharmaceuticals: Consultancy; Adaptive Technologies: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding. Quach:Amgen, sanofi, celgene, Karyopharm, GSK: Research Funding; Amgen, Celgene, karyopharm, GSK, Janssen Cilag, Sanofi.: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline, Karyopharm, Amgen, Celgene, Janssen Cilag: Consultancy; GlaxoSmithKline, Karyopharm, Amgen, Celgene, Janssen Cilag: Honoraria. Trudel:Celgene, Janssen, Takeda, Sanofi, Karyopharm, Amgen Canada: Honoraria; Celgene, Amgen, GSK: Consultancy, Research Funding; GSK, Celgene, Janssen, Amgen, Genentech: Research Funding. Routledge:Celgene, Sandoz: Consultancy; Amgen, BMS, Celgene, Sandoz: Honoraria. Song:Otsuka: Honoraria; Janssen: Honoraria, Research Funding; Amgen, Celgene,Takeda: Consultancy, Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Paul:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Khan:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Brouch:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Ferron-Brady:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Yeakey:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Shelton:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Montes de Oca:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Smith:SpringWorks: Current Employment, Current equity holder in publicly-traded company. Im:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Ahlers:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Paul:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Holkova:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Gupta:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company; Novartis: Current equity holder in publicly-traded company. Kremer:GlaxoSmithKline: Current Employment, Current equity holder in publicly-traded company. Rodriguez-Otero:GlaxoSmithKline: Consultancy, Current Employment, Current equity holder in publicly-traded company, Honoraria; Kite: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Medscape: Membership on an entity's Board of Directors or advisory committees; Celgene/Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Janssen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Sanofi: Consultancy, Honoraria.


2016 ◽  
Vol 118 (2) ◽  
pp. 1-33
Author(s):  
H. Kenny Nienhusser ◽  
Blanca E. Vega ◽  
Mariella Cristina Saavedra Carquin

Background/Context Although millions of undocumented students are enrolled in and guaranteed free public K—12 education, their postsecondary education opportunities are stifled. Some of the barriers encountered by undocumented students include discriminatory public policies, limited availability of information and insensitive college choice processes, and fear of immigration status disclosure. Research Question The research question that guided this study was: How, if at all, do undocumented students experience microaggressions during their college choice process ? Research Participants A total of 15 undocumented immigrants were interviewed and consisted of 10 females and 5 males. Twelve identified as Latina/o and 3 as Asian. Two participants never enrolled in postsecondary education. Of the 13 participants who enrolled in postsecondary education, 12 enrolled in a New York State public institution (one attended a public out-of-state university). Nine of the interviewees initially attended a four-year college, and 4 originally enrolled in a two-year institution. Research Design This qualitative phenomenological study included in-depth semistructured interviews with 15 undocumented students who attended New York City high schools. Findings The findings identify nine themes in the area of microaggressions that research participants faced during their college choice process: discriminatory financial aid policies, restricted college choice information, constrained life opportunities, denial of college opportunities, insensitive behaviors, insensitive college choice processes, narrowed college expectations, fear of coming out, and undocumented immigrant blindness. Every respondent who participated in our study encountered multiple episodes of these microaggressions in their college choice process. We found that the participants faced cumulative and negative messages, behaviors, and environmental cues that pervaded their college choice process. Also, seemingly well-intentioned institutional agents often delivered many of the microaggressions encountered by students. Conclusions The authors conclude the need to eliminate discriminatory postsecondary education policies that shape the educational journeys of undocumented students. Also, they challenge education institutional agents to create environments and processes that better address undocumented students’ college access needs.


Sign in / Sign up

Export Citation Format

Share Document